Literature DB >> 16253964

Drug-induced apoptosis was markedly attenuated in endometriotic stromal cells.

Masao Izawa1, Tasuku Harada, Imari Deura, Fuminori Taniguchi, Tomio Iwabe, Naoki Terakawa.   

Abstract

BACKGROUND: The survival of endometriotic cells in the ectopic site has been investigated from the aspect of susceptibility of endometriotic tissues to apoptosis. In order to investigate the nature of abnormal survival of endometriotic cells in ectopic locations, we compared drug-induced apoptosis in endometrial and endometriotic cells.
METHODS: Endometrial stromal cells were obtained from normal endometrium in 11 patients who underwent hysterectomy for leiomyoma without endometriosis. Endometriotic cells were isolated from the chocolate cyst linings of the ovary in 13 patients who underwent laparoscopic surgery. Cells were cultured in the presence or absence of staurosporine. Apoptotic cell death was evaluated by staining nuclei with propidium iodide and phosphatidylserine (a marker of early apoptotic events) with Annexin V as well as by DNA fragmentation assay. The number of viable cells was estimated by modified MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide WST-8] assay.
RESULTS: After 3 h of exposure to staurosporine, >50% of the endometrial stromal cells became Annexin V positive. In contrast, >30% of the endometriotic cells were Annexin V positive. DNA fragmentation was not clearly induced in the endometriotic cells. Less than 20% of the endometrial cells survived after staurosporine exposure, while >40% of the endometriotic cells survived. Cell death induced by staurosporine was partially blocked by incubation with the caspase inhibitor, N-benzyoxycarbonyl-Val-Ala-Asp(OMe)fluoromethyl-ketone (ZVAD-fmk), suggesting that a caspase cascade may play a role in the cell death process.
CONCLUSIONS: Attenuated susceptibility to apoptosis in endometriotic stromal cells may be associated with abnormal survival in ectopic sites in an environment that is probably unfavourable. These results may be implicated in the pathophysiology of endometriosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253964     DOI: 10.1093/humrep/dei372

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Dual inhibition of ERK1/2 and AKT pathways is required to suppress the growth and survival of endometriotic cells and lesions.

Authors:  Joe A Arosh; Sakhila K Banu
Journal:  Mol Cell Endocrinol       Date:  2018-12-20       Impact factor: 4.102

2.  Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis.

Authors:  Takashi Uegaki; Fuminori Taniguchi; Kazuomi Nakamura; Mitsuhiko Osaki; Futoshi Okada; Osamu Yamamoto; Tasuku Harada
Journal:  Hum Reprod       Date:  2014-11-05       Impact factor: 6.918

Review 3.  Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis.

Authors:  Fernando M Reis; Felice Petraglia; Robert N Taylor
Journal:  Hum Reprod Update       Date:  2013-03-28       Impact factor: 15.610

4.  Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms.

Authors:  Sakhila K Banu; JeHoon Lee; V O Speights; Anna Starzinski-Powitz; Joe A Arosh
Journal:  Mol Endocrinol       Date:  2009-04-30

5.  Study of ultrastructure and apoptosis in the endometrium of women with or without endometriosis.

Authors:  Leila Roshangar; Seddighe Abdollahifard; Abbas Majdi; Armin Zarrintan; Alia Ghasemzade; Laaia Farzadi; Sara Soleimani Rad; Jafar Soleimani Rad
Journal:  Iran J Reprod Med       Date:  2013-05

6.  Toll-Like Receptor 2 Expression as a New Hallmark of Advanced Endometriosis.

Authors:  Małgorzata Sobstyl; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Izabela Korona-Głowniak; Anna Sobstyl; Wiesława Bednarek; Jacek Roliński
Journal:  Cells       Date:  2020-07-30       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.